ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Vivos Therapeutics, Inc. (VVOS) stock declined over -0.78%, trading at $2.55 on NASDAQ, down from the previous close of $2.57. The stock opened at $2.49, fluctuating between $2.42 and $2.64 in the recent session.
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Employees | 114 |
Beta | 7.44 |
Sales or Revenue | $13.80M |
5Y Sales Change% | 0.379% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Medical - Devices |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com